吸入用布地奈德混悬液联合复方异丙托溴铵雾化液治疗慢阻肺急性加重期的效果分析

Effect Analysis of Inhalation Budesonide Suspension Combined with Compound Ipratropium Bromide Aerosol in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease

目的观察慢阻肺急性加重阶段以吸入布地奈德混悬液配合复方异丙托溴铵雾化液方式实施诊治的效果。方法收取2018年12月—2020年1月期间该院接诊的86例慢阻肺且在加重期的患者进行研究,以双盲法将其划分成对照组(n=43)和治疗组(n=43),实施单一用药者(布地奈德混悬液)纳入对照组,采取联合用药者(布地奈德混悬液+复方异丙托溴铵)纳入治疗组,对两组疗效实施比较。结果治疗组临床效率相95.35%比于对照组79.07%提升效果显著(χ^2=5.108,P=0.024);治疗组PaO2(10.53±2.41)k Pa、PaCO2(6.11±1.76)k Pa指标较对照组(9.01±2.34)k Pa、(7.03±1.52)k Pa明显改善(t=2.967、2.594,P=0.004、0.011);与对照组FEV1/FVC (57.01±7.68)%、FEV(55.45±4.89)L比,治疗组FEV1/FVC(65.36±7.01)%、FEV(62.31±4.71)L显著提升(t=5.266、6.626,P<0.001)。结论慢阻肺急性加重阶段应用吸入布地奈德混悬液配合复方异丙托溴铵雾化液诊治效果较为理想。

Objective To observe the diagnosis and treatment effect of inhalation of budesonide suspension and compound ipratropium bromide atomization solution in the acute exacerbation stage of COPD. Methods This study collected 86 patients with COPD in the exacerbation phase who were admitted to the hospital from December 2018 to January 2020 for research, and divided them into a control group(n =43) and a treatment group(n =43), the single medication(budesonide suspension) was included in the control group, and the combined medication(budesonide suspension + compound ipratropium bromide) was included in the treatment group, and the efficacy of the two groups was compared. Results The clinical efficiency of the treatment group was 95.35% compared with the control group’s79.07% improvement effect(χ^2=5.108, P=0.024);the treatment group’s PaO2(10.53±2.41)kPa and PaCO2(6.11±1.76)kPa indicators were higher than those of the control group(9.01± 2.34)kPa,(7.03±1.52)kPa were significantly improved(t=2.967, 2.594, P=0.004, 0.011);compared with the control group FEV1/FEV(57.01±7.68)%, FEV(55.45±4.89) L, the treatment group FEV1/FVC(65.36 ±7.01)%, FEV(62.31 ±4.71)L significantly improved(t =5.266, 6.626, P <0.001).Conclusion The diagnosis and treatment effect of inhaled budesonide suspension combined with compound ipratropium bromide aerosol in the acute exacerbation stage of COPD is ideal.